Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 11/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560606 | 0.87 | TYMS (0.40) | — | |
| SCHEMBL3502995 | 0.85 | P2RY6 (0.40) | P2RY6P2RY2P2RY4 | |
| SCHEMBL6519315 | 0.76 | P2RY6 (0.73) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL6519317 | 0.76 | P2RY6 (0.73) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL1763346 | 0.73 | POLG (0.42) | P2RY6P2RY2P2RY4 | |
| SCHEMBL5989008 | 0.73 | P2RY6 (0.47) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL4463943 | 0.73 | P2RY6 (0.48) | P2RY6P2RY2DNPH1 | |
| SCHEMBL11134131 | 0.71 | TK2 (0.53) | P2RY6P2RY2 | |
| SCHEMBL8437048 | 0.71 | P2RY2 (0.58) | P2RY6P2RY2P2RY4 | |
| SCHEMBL547184 | 0.71 | DNPH1 (0.49) | P2RY6DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20220372158-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2022-11-24 | — | — | US | claimed |
| US-11421038-B2 | RNA-coded antibody | CUREVAC AG (DE) | 2022-08-23 | — | — | US | claimed |
| EP-3115064-B1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2021-11-24 | — | — | EP | claimed |
| EP-3636669-A1 | RNA-CODED ANTIBODY | CureVac AG (DE) | 2020-04-15 | — | — | EP | claimed |
| US-20190284260-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2019-09-19 | — | — | US | claimed |
| EP-3329941-A1 | RNA-CODED BISPECIFIC ANTIBODY | CureVac AG (DE) | 2018-06-06 | — | — | EP | claimed |
| EP-3118224-A1 | RNA-CODED ANTIBODY | CureVac AG (DE) | 2017-01-18 | — | — | EP | claimed |
| EP-3115064-A1 | RNA-CODED ANTIBODY | CureVac AG (DE) | 2017-01-11 | — | — | EP | claimed |
| US-20160166690-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-16 | — | — | US | claimed |
| US-20160168254-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-16 | — | — | US | claimed |
| US-20160166691-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-16 | — | — | US | claimed |
| US-20160166692-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-16 | — | — | US | claimed |
| US-20160152706-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-02 | — | — | US | claimed |
| US-20160152691-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-06-02 | — | — | US | claimed |
| US-20160145346-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2016-05-26 | — | — | US | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2101823-A2 | RNA-CODED ANTIBODY | Curevac GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008083949-A2 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2008-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152691-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20160166691-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20160145346-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20160152706-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20160166692-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20160166690-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY6 3298/4885P2RY2 3741/4885DNPH1 4191/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY6 3298/4885P2RY2 3741/4885DNPH1 4191/4885 |
| US-20160168254-A1 | RNA-CODED ANTIBODY | TRDMT1, NSUN3, POLRMT | P2RY6 3779/4885P2RY2 3997/4885DNPH1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.